Co-administration of low doses of intranasal PT-141, a melanocortin receptor agonist, and sildenafil to men with erectile dysfunction results in an enhanced erectile response

This randomized controlled trial investigated the effects of combining low-dose intranasal PT-141 (bremelanotide) with sildenafil in 19 men with erectile dysfunction (ED). The study found that the combination significantly enhanced erectile response during visual sexual stimulation compared to sildenafil alone, without increasing adverse events. PT-141, a melanocortin receptor agonist, acts